The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Subscribe To Our Newsletter & Stay Updated
